These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34187185)

  • 1. Effect of Liraglutide on Arterial Inflammation Assessed as [
    Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
    Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
    van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
    Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
    Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Jendle J; Hyötyläinen T; Orešič M; Nyström T
    Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
    JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
    Tanaka K; Okada Y; Tokutsu A; Tanaka Y
    Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [
    Jensen JK; Zobel EH; von Scholten BJ; Rotbain Curovic V; Hansen TW; Rossing P; Kjaer A; Ripa RS
    Front Endocrinol (Lausanne); 2021; 12():790405. PubMed ID: 34917038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
    Rizzo M; Rizvi AA; Patti AM; Nikolic D; Giglio RV; Castellino G; Li Volti G; Caprio M; Montalto G; Provenzano V; Genovese S; Ceriello A
    Cardiovasc Diabetol; 2016 Dec; 15(1):162. PubMed ID: 27912784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
    Duivenvoorden R; Mani V; Woodward M; Kallend D; Suchankova G; Fuster V; Rudd JHF; Tawakol A; Farkouh ME; Fayad ZA
    JACC Cardiovasc Imaging; 2013 Oct; 6(10):1087-1094. PubMed ID: 24135322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial.
    Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R
    BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
    Zhang J; Xian TZ; Wu MX; Li C; Pan Q; Guo LX
    Cardiovasc Diabetol; 2020 Apr; 19(1):48. PubMed ID: 32334592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.